Cardiovascular and metabolic safety profiles of the fluoroquinolones

Bibliography

• Pfaller MA, Jones RN, Marshall SA, Inducible amp C beta-lactamase producing gram-negative bacilli from blood stream infections: frequency, antimicrobial susceptibility, and molecular epidemiology in a national surveillance program (SCOPE). Diagn Microbiol Infect Dis 1997;28(4):211-19
   PubMed Web of Science ®Google Scholar
• Neu HC. The crisis in antibiotic resistance. Science 1992;257(5073):1064-73
   PubMed Web of Science ®Google Scholar
• Urbanek K, Kolar M, Strojil J, Utilization of fluoroquinolones and Escherichia coli resistance in urinary tract infection: inpatients and outpatients. Pharmacoepidemiol Drug Saf 2005;14(10):741-5
   PubMed Web of Science ®Google Scholar
• Elseviers MM, Ferech M, Vander Stichele RH, Antibiotic use in ambulatory care in Europe (ESAC data 1997-2002): trends, regional differences and seasonal fluctuations. Pharmacoepidemiol Drug Saf 2007;16(1):115-23
   PubMed Web of Science ®Google Scholar
• Vander Stichele RH, Elseviers MM, Ferech M, European surveillance of antimicrobial consumption (ESAC): data collection performance and methodological approach. Br J Clin Pharmacol 2004;58(4):419-28
   PubMed Web of Science ®Google Scholar
• OsMed. OsMed - L'uso dei Farmaci in Italia - Rapporto Nazionale; 2008
   Google Scholar
• OsMed. OsMed - L'uso dei Farmaci in Italia - Rapporto Nazionale; 2009
   Google Scholar
• Mehlhorn AJ, Brown DA. Safety concerns with fluoroquinolones. Ann Pharmacother 2007;41(11):1859-66
   PubMed Web of Science ®Google Scholar
• Mohr JF, McKinnon PS, Peymann PJ, A retrospective, comparative evaluation of dysglycemias in hospitalized patients receiving gatifloxacin, levofloxacin, ciprofloxacin, or ceftriaxone. Pharmacotherapy 2005;25(10):1303-9
   PubMed Web of Science ®Google Scholar
• Owens RC Jr, Ambrose PG. Clinical use of the fluoroquinolones. Med Clin North Am 2000;84(6):1447-69
   PubMed Web of Science ®Google Scholar
• Owens RC Jr, Bhavnani SM, Ambrose PG. Assessment of pharmacokinetic-pharmacodynamic target attainment of gemifloxacin against Streptococcus pneumoniae. Diagn Microbiol Infect Dis 2005;51(1):45-9
   PubMed Web of Science ®Google Scholar
• Yew WW. Management of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: current status and future prospects. Kekkaku 2011;86(1):9-16
   PubMedGoogle Scholar
• WHO. Treatment of tuberculosis: guidelines. 4th edition. 2009
   Google Scholar
• Goossens H, Ferech M, Vander Stichele R, Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet 2005;365(9459):579-87
   PubMed Web of Science ®Google Scholar
• Owens RC Jr, Ambrose PG. Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis 2005;41(Suppl 2):S144-57
   PubMed Web of Science ®Google Scholar
• Liu HH. Safety profile of the fluoroquinolones: focus on levofloxacin. Drug Saf 2010;33(5):353-69
   PubMed Web of Science ®Google Scholar
• Frothingham R. Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin. Pharmacotherapy 2001;21(12):1468-72
   PubMed Web of Science ®Google Scholar
• Frothingham R. Glucose homeostasis abnormalities associated with use of gatifloxacin. Clin Infect Dis 2005;41(9):1269-76
   PubMed Web of Science ®Google Scholar
• Haerian H, McHugh P, Brown R, Gatifloxacin produces both hypoglycemia and hyperglycemia: a retrospective study. Am J Med Sci 2008;335(2):95-8
   PubMed Web of Science ®Google Scholar
• Lapi F, Tuccori M, Motola D, Safety profile of the fluoroquinolones: analysis of adverse drug reactions in relation to prescription data using four regional pharmacovigilance databases in Italy. Drug Saf 2010;33(9):789-99
   PubMed Web of Science ®Google Scholar
• Leone R, Venegoni M, Motola D, Adverse drug reactions related to the use of fluoroquinolone antimicrobials: an analysis of spontaneous reports and fluoroquinolone consumption data from three Italian regions. Drug Saf 2003;26(2):109-20
   PubMed Web of Science ®Google Scholar
• Zambon A, Polo Friz H, Contiero P, Effect of macrolide and fluoroquinolone antibacterials on the risk of ventricular arrhythmia and cardiac arrest: an observational study in Italy using case-control, case-crossover and case-time-control designs. Drug Saf 2009;32(2):159-67
   PubMed Web of Science ®Google Scholar
• Rosignoli MT, Di Loreto G, Dionisio P. Effects of prulifloxacin on cardiac repolarization in healthy subjects: a randomized, crossover, double-blind versus placebo, moxifloxacin-controlled study. Clin Drug Investig 2010;30(1):5-14
   PubMed Web of Science ®Google Scholar
• Keam SJ, Perry CM. Prulifloxacin. Drugs 2004;64(19):2221-34; discussion 35-6
   PubMed Web of Science ®Google Scholar
• Aspinall SL, Good CB, Jiang R, Severe dysglycemia with the fluoroquinolones: a class effect? Clin Infect Dis 2009;49(3):402-8
   PubMed Web of Science ®Google Scholar
• Lode H. Safety and tolerability of commonly prescribed oral antibiotics for the treatment of respiratory tract infections. Am J Med 2010;123(4 Suppl):S26-38
   PubMedGoogle Scholar
• EMEA/CHMP/PhVWP/810358. Pharmacovigilance Working Party (PhVWP) 2010(1012)
   Google Scholar
• Lewis RJ, Mohr JF III. Dysglycaemias and fluoroquinolones. Drug Saf 2008;31(4):283-92
   PubMed Web of Science ®Google Scholar
• Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000;356(9237):1255-9
   PubMed Web of Science ®Google Scholar
• Aronson JK, Hauben M. Anecdotes that provide definitive evidence. BMJ 2006;333(7581):1267-9
   PubMed Web of Science ®Google Scholar
• Atasoy H, Erdem G, Ceyhan M, Hypertension associated with ciprofloxacin use in an infant. Ann Pharmacother 1995;29(10):1049
   PubMed Web of Science ®Google Scholar
• Samaha FF. QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin. Am J Med 1999;107(5):528-9
   PubMed Web of Science ®Google Scholar
• Iannini PB, Doddamani S, Byazrova E, Risk of torsades de pointes with non-cardiac drugs. Prolongation of QT interval is probably a class effect of fluoroquinolones. BMJ 2001;322(7277):46-7
   PubMed Web of Science ®Google Scholar
• Siepmann M, Kirch W. Drug points: tachycardia associated with moxifloxacin. BMJ 2001;322(7277):23
   PubMed Web of Science ®Google Scholar
• Paltoo B, O'Donoghue S, Mousavi MS. Levofloxacin induced polymorphic ventricular tachycardia with normal QT interval. Pacing Clin Electrophysiol 2001;24(5):895-7
   PubMed Web of Science ®Google Scholar
• Gandhi PJ, Menezes PA, Vu HT, Fluconazole- and levofloxacin-induced torsades de pointes in an intensive care unit patient. Am J Health Syst Pharm 2003;60(23):2479-83
   PubMed Web of Science ®Google Scholar
• Amankwa K, Krishnan SC, Tisdale JE. Torsades de pointes associated with fluoroquinolones: importance of concomitant risk factors. Clin Pharmacol Ther 2004;75(3):242-7
   PubMed Web of Science ®Google Scholar
• Prabhakar M, Krahn AD. Ciprofloxacin-induced acquired long QT syndrome. Heart Rhythm 2004;1(5):624-6
   PubMed Web of Science ®Google Scholar
• Daya SK, Gowda RM, Khan IA. Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis. Am J Ther 2004;11(1):77-9
   PubMedGoogle Scholar
• Flyer JL. Identifying patients at risk for QT interval prolongation: case studies. J Fam Pract 2005(Suppl):S18-19
   Google Scholar
• Nykamp DL, Blackmon CL, Schmidt PE, QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine. Ann Pharmacother 2005;39(3):543-6
   PubMed Web of Science ®Google Scholar
• Flanagan MC, Mitchell ES, Haigney MC. Ciprofloxacin-induced torsade de pointes. Int J Cardiol 2006;113(2):239-41
   PubMed Web of Science ®Google Scholar
• Letsas KP, Sideris A, Kounas SP, Drug-induced QT interval prolongation after ciprofloxacin administration in a patient receiving olanzapine. Int J Cardiol 2006;109(2):273-4
   PubMed Web of Science ®Google Scholar
• Altin T, Ozcan O, Turhan S, Torsade de pointes associated with moxifloxacin: a rare but potentially fatal adverse event. Can J Cardiol 2007;23(11):907-8
   PubMed Web of Science ®Google Scholar
• Kazmierczak J, Peregud-Pogorzelska M, Rzeuski R. QT Interval prolongation and torsades de pointes due to a coadministration of ciprofloxacin and azimilide in a patient with implantable cardioverter-defibrillator. Pacing Clin Electrophysiol 2007;30(8):1043-6
   PubMed Web of Science ®Google Scholar
• Knorr JP, Moshfeghi M, Sokoloski MC. Ciprofloxacin-induced Q-T interval prolongation. Am J Health Syst Pharm 2008;65(6):547-51
   PubMed Web of Science ®Google Scholar
• Nair MK, Patel K, Starer PJ. Ciprofloxacin-induced torsades de pointes in a methadone-dependent patient. Addiction 2008;103(12):2062-4
   PubMed Web of Science ®Google Scholar
• Keivanidou A, Arnaoutoglou C, Krommydas A, Ciprofloxacin induced acquired long QT syndrome in a patient under class III antiarrhythmic therapy. Cardiol J 2009;16(2):172-4
   PubMed Web of Science ®Google Scholar
• Zeineh NS. A toxic combination. Am J Med 2010;123(8):707-8
   PubMed Web of Science ®Google Scholar
• Patel PD, Afshar H, Birnbaum Y. Levofloxacin-induced torsades de pointes. Tex Heart Inst J 2010;37(2):216-17
   PubMed Web of Science ®Google Scholar
• Salinas Arce J, Romero R, Solorzano P. A case of prolonged QT interval and torsades de pointes due to ciprofloxacin. Rev Esp Cardiol 2010;63(1):111-12
   PubMed Web of Science ®Google Scholar
• Ibrahim M, Omar B. Ciprofloxacin-induced torsade de pointes. Am J Emerg Med 2010. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Roberge RJ, Kaplan R, Frank R, Glyburide-ciprofloxacin interaction with resistant hypoglycemia. Ann Emerg Med 2000;36(2):160-3
   PubMed Web of Science ®Google Scholar
• Bharani A, Kumar H. Drug points: diabetes inspidus induced by ofloxacin. BMJ 2001;323(7312):547
   PubMed Web of Science ®Google Scholar
• Lin G, Hays DP, Spillane L. Refractory hypoglycemia from ciprofloxacin and glyburide interaction. J Toxicol Clin Toxicol 2004;42(3):295-7
   PubMed Web of Science ®Google Scholar
• Friedrich LV, Dougherty R. Fatal hypoglycemia associated with levofloxacin. Pharmacotherapy 2004;24(12):1807-12
   PubMed Web of Science ®Google Scholar
• Lawrence KR, Adra M, Keir C. Hypoglycemia-induced anoxic brain injury possibly associated with levofloxacin. J Infect 2006;52(6):e177-80
   PubMedGoogle Scholar
• Wang S, Rizvi AA. Levofloxacin-induced hypoglycemia in a nondiabetic patient. Am J Med Sci 2006;331(6):334-5
   PubMed Web of Science ®Google Scholar
• Kanbay M, Aydogan T, Bozalan R, A rare but serious side effect of Levofloxacin: hypoglycemia in a geriatric patient. Diabetes Care 2006;29(7):1716-17
   PubMed Web of Science ®Google Scholar
• Singh M, Jacob JJ, Kapoor R, Fatal hypoglycemia with levofloxacin use in an elderly patient in the post-operative period. Langenbecks Arch Surg 2008;393(2):235-8
   PubMed Web of Science ®Google Scholar
• Vallurupalli S, Huesmann G, Gregory J, Levofloxacin-associated hypoglycaemia complicated by pontine myelinolysis and quadriplegia. Diabet Med 2008;25(7):856-9
   PubMed Web of Science ®Google Scholar
• Gibert AE, Porta FS. Hypoglycemia and levofloxacin: a case report. Clin Infect Dis 2008;46(7):1126-7
   PubMed Web of Science ®Google Scholar
• Kelesidis T, Canseco E. Levofloxacin-induced hypoglycemia: a rare but life-threatening side effect of a widely used antibiotic. Am J Med 2009;122(3):e3-4
   PubMed Web of Science ®Google Scholar
• Garber SM, Pound MW, Miller SM. Hypoglycemia associated with the use of levofloxacin. Am J Health Syst Pharm 2009;66(11):1014-19
   PubMed Web of Science ®Google Scholar
• Kelesidis T, Canseco E. Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect. Am J Med 2010;123(2):e5-6
   PubMedGoogle Scholar
• Yamaguchi H, Kawai H, Matsumoto T, Post-marketing surveillance of the safety of levofloxacin in Japan. Chemotherapy 2007;53(2):85-103
   PubMed Web of Science ®Google Scholar
• Poluzzi E, Raschi E, Motola D, Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA Adverse Event Reporting System. Drug Saf 2010;33(4):303-14
   PubMed Web of Science ®Google Scholar
• Clark DW, Layton D, Wilton LV, Profiles of hepatic and dysrhythmic cardiovascular events following use of fluoroquinolone antibacterials: experience from large cohorts from the Drug Safety Research Unit Prescription-Event Monitoring database. Drug Saf 2001;24(15):1143-54
   PubMed Web of Science ®Google Scholar
• Corrao G, Botteri E, Bagnardi V, Generating signals of drug-adverse effects from prescription databases and application to the risk of arrhythmia associated with antibacterials. Pharmacoepidemiol Drug Saf 2005;14(1):31-40
   PubMed Web of Science ®Google Scholar
• Corrao G, Botteri E, Bertu L, Exploring the effect of transient exposure on the risk of acute events by means of time-window designs: an application to fluoroquinolone antibacterials and arrhythmia. Pharmacoepidemiol Drug Saf 2006;15(1):31-7
   PubMed Web of Science ®Google Scholar
• Makaryus AN, Byrns K, Makaryus MN, Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant “clinical” event? South Med J 2006;99(1):52-6
   PubMed Web of Science ®Google Scholar
• Meropol SB, Chan KA, Chen Z, Adverse events associated with prolonged antibiotic use. Pharmacoepidemiol Drug Saf 2008;17(5):523-32
   PubMed Web of Science ®Google Scholar
• Coblio NA, Mowrey K, McCright P, Use of a data warehouse to examine the effect of fluoroquinolones on glucose metabolism. Am J Health Syst Pharm 2004;61(23):2545-8
   PubMed Web of Science ®Google Scholar
• Graumlich JF, Habis S, Avelino RR, Hypoglycemia in inpatients after gatifloxacin or levofloxacin therapy: nested case-control study. Pharmacotherapy 2005;25(10):1296-302
   PubMed Web of Science ®Google Scholar
• Park-Wyllie LY, Juurlink DN, Kopp A, Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med 2006;354(13):1352-61
   PubMed Web of Science ®Google Scholar
• Lodise T, Graves J, Miller C, Effects of gatifloxacin and levofloxacin on rates of hypoglycemia and hyperglycemia among elderly hospitalized patients. Pharmacotherapy 2007;27(11):1498-505
   PubMed Web of Science ®Google Scholar
• LaPlante KL, Mersfelder TL, Ward KE, Prevalence of and risk factors for dysglycemia in patients receiving gatifloxacin and levofloxacin in an outpatient setting. Pharmacotherapy 2008;28(1):82-9
   PubMed Web of Science ®Google Scholar
• Basyigit I, Kahraman G, Ilgazli A, The effects of levofloxacin on ECG parameters and late potentials. Am J Ther 2005;12(5):407-10
   PubMedGoogle Scholar
• Demolis JL, Kubitza D, Tenneze L, Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects. Clin Pharmacol Ther 2000;68(6):658-66
   PubMed Web of Science ®Google Scholar
• Gajjar DA, LaCreta FP, Kollia GD, Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise. Pharmacotherapy 2000;20(6 Pt 2):76S-86S
   PubMed Web of Science ®Google Scholar
• Noel GJ, Natarajan J, Chien S, Effects of three fluoroquinolones on QT interval in healthy adults after single doses. Clin Pharmacol Ther 2003;73(4):292-303
   PubMed Web of Science ®Google Scholar
• Noel GJ, Goodman DB, Chien S, Measuring the effects of supratherapeutic doses of levofloxacin on healthy volunteers using four methods of QT correction and periodic and continuous ECG recordings. J Clin Pharmacol 2004;44(5):464-73
   PubMed Web of Science ®Google Scholar
• Morganroth J, Dimarco JP, Anzueto A, A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community-acquired pneumonia. Chest 2005;128(5):3398-406
   PubMed Web of Science ®Google Scholar
• Tsikouris JP, Peeters MJ, Cox CD, Effects of three fluoroquinolones on QT analysis after standard treatment courses. Ann Noninvasive Electrocardiol 2006;11(1):52-6
   PubMed Web of Science ®Google Scholar
• Taubel J, Naseem A, Harada T, Levofloxacin can be used effectively as a positive control in thorough QT/QTc studies in healthy volunteers. Br J Clin Pharmacol 2010;69(4):391-400
   PubMed Web of Science ®Google Scholar
• Sanguinetti MC, Jiang C, Curran ME, A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 1995;81(2):299-307
   PubMed Web of Science ®Google Scholar
• Malik M, Hnatkova K, Schmidt A, Electrocardiographic QTc changes due to moxifloxacin infusion. J Clin Pharmacol 2009;49(6):674-83
   PubMed Web of Science ®Google Scholar
• Glass SK, Pearl DL, McEwen SA, A province-level risk factor analysis of fluoroquinolone consumption patterns in Canada (2000-06). J Antimicrob Chemother 2010;65(9):2019-27
   PubMed Web of Science ®Google Scholar
• Ferech M, Coenen S, Malhotra-Kumar S, European Surveillance of Antimicrobial Consumption (ESAC): outpatient quinolone use in Europe. J Antimicrob Chemother 2006;58(2):423-7
   PubMed Web of Science ®Google Scholar
• Bouchrif B, Paglietti B, Murgia M, Prevalence and antibiotic-resistance of Salmonella isolated from food in Morocco. J Infect Dev Ctries 2009;3(1):35-40
   PubMed Web of Science ®Google Scholar
• Meng CY, Smith BL, Bodhidatta L, Etiology of diarrhea in young children and patterns of antibiotic resistance in Cambodia. Pediatr Infect Dis J 2011;30(4):331-5
   PubMed Web of Science ®Google Scholar
• Yanagi D, De Vries GC, Rahardjo D, Emergence of fluoroquinolone-resistant strains of Salmonella enterica in Surabaya, Indonesia. Diagn Microbiol Infect Dis 2009;64(4):422-6
   PubMed Web of Science ®Google Scholar
• Lacroix P, Crumb WJ, Durando L, Prulifloxacin: in vitro (HERG current) and in vivo (conscious dog) assessment of cardiac risk. Eur J Pharmacol 2003;477(1):69-72
   PubMed Web of Science ®Google Scholar
• Gallelli L, Gallelli A, Vero G, Acute renal failure probably induced by prulifloxacin in an elderly woman : a first case report. Clin Drug Investig 2006;26(1):49-53
   PubMed Web of Science ®Google Scholar
• Stahlmann R, Lode H. Safety considerations of fluoroquinolones in the elderly: an update. Drugs Aging 2010;27(3):193-209
   PubMed Web of Science ®Google Scholar
• Maeda N, Tamagawa T, Niki I, Increase in insulin release from rat pancreatic islets by quinolone antibiotics. Br J Pharmacol 1996;117(2):372-6
   PubMed Web of Science ®Google Scholar
• Ge TF, Law PY, Wong HY, Gatifloxacin affects GLUT1 gene expression and disturbs glucose homeostasis in vitro. Eur J Pharmacol 2007;573(1-3):70-4
   PubMed Web of Science ®Google Scholar
• McGowan KM, Long SD, Pekala PH. Glucose transporter gene expression: regulation of transcription and mRNA stability. Pharmacol Ther 1995;66(3):465-505
   PubMed Web of Science ®Google Scholar
• Zimmerli W. Clinical practice. Vertebral osteomyelitis. N Engl J Med 2010;362(11):1022-9
   PubMed Web of Science ®Google Scholar
• Zimmerli W, Trampuz A, Ochsner PE. Prosthetic-joint infections. N Engl J Med 2004;351(16):1645-54
   PubMed Web of Science ®Google Scholar